TL;DR
This study investigates the role of the PAX6 gene in microcornea, a rare condition where the cornea is smaller than normal. Researchers identified PAX6 mutations in 11.4% of families with microcornea, suggesting it's a more common cause than previously thought and expanding our understanding of PAX6-related eye disorders.
What Problem Does This Paper Address?
Microcornea, characterized by a corneal diameter less than 10 mm, is a congenital eye condition that can occur in isolation or alongside other developmental anomalies. While PAX6 mutations are well-established as a major cause of aniridia (absence of the iris) and are sometimes associated with microcornea, a comprehensive evaluation of PAX6 as a primary cause of microcornea, especially when it's the most prominent sign, had not been reported. This study aims to fill that gap by systematically screening for PAX6 mutations in families where microcornea is the main ocular feature.
Methods
The researchers employed standard molecular biology techniques. Genomic DNA was extracted from 35 families presenting with microcornea. The coding regions of the PAX6 gene were amplified using PCR and then sequenced via Sanger sequencing. Novel variations identified were further validated by sequencing in 192 normal control individuals to rule out common polymorphisms. Bioinformatics tools, specifically PolyPhen-2 and SIFT, were utilized to predict the potential structural and functional consequences of the identified mutations on the PAX6 protein. Cosegregation analysis was also performed in available family members to confirm the link between the mutations and the phenotype.
Datasets
The study utilized DNA samples from 35 families with microcornea, collected through the Hereditary Eye Disease Genomic DNA Repository at Zhongshan Ophthalmic Center. Additionally, DNA from 192 normal individuals was used as a control group for variant validation.
Key Insights and Ideas
- PAX6 is a significant contributor to microcornea: The finding that 11.4% of microcornea cases in this cohort are linked to PAX6 mutations challenges the notion that it's only a rare association.
- Expanding the PAX6 mutation spectrum: The identification of two novel PAX6 mutations (c.83_85delAGA and c.337G>C) alongside a known mutation (c.399_399+5del6) broadens the known repertoire of genetic alterations in PAX6 associated with ocular development.
- Phenotypic variability: Even within the same family and with the same mutation (e.g., c.83_85delAGA in family 71987), there can be significant differences in the severity of ocular manifestations, highlighting the complex interplay of genetic and environmental factors.
- PAX6's role in iris development: While aniridia is a hallmark of PAX6 mutations, this study shows that milder iris anomalies, such as partial iris or iris hypoplasia, are also frequently observed in microcornea patients with PAX6 mutations.
Key Results
- Three heterozygous PAX6 mutations were identified in four out of 35 families (11.4%) with microcornea.
- Two novel mutations were discovered: c.83_85delAGA (p.Lys28del) in two families and c.337G>C (p.Ala113Pro) in one family.
- A previously reported mutation, c.399_399+5del6 (p.Lys134Ser_fsX12), was found in one family.
- None of these identified variations were present in the 192 normal control individuals.
- All identified mutations were located within the paired box domain of the PAX6 gene.
- Patients with these mutations often presented with microcornea, nystagmus, and varying degrees of iris anomalies (partial iris or iris hypoplasia). Other observed anomalies included ptosis, mild optic nerve hypoplasia, bilateral foveal hypoplasia, corneal opacity, and posterior lamellar lens opacity.
Limitations and Future Work
The authors acknowledge that the study focused on a specific cohort of Chinese patients, and further studies with larger, diverse populations are needed to confirm the prevalence of PAX6 mutations in microcornea globally. The precise functional mechanisms by which these PAX6 mutations lead to microcornea, especially the dominant-negative effects and haploinsufficiency, warrant further investigation. The study also suggests that the effect of these mutations on PAX6 expression and the role of other modulating factors in ocular development require deeper exploration. Future work could involve investigating the impact of these mutations on PAX6 protein function through in vitro studies and exploring the broader spectrum of ocular phenotypes associated with PAX6 mutations in microcornea.
Summary updated